CNS Pharmaceuticals Call to Discuss FDA IND Approval and Phase 2 Trial for Berubicin Today at 8:30am ET Dec 18, 2020 8:00am EST
CNS Pharmaceuticals Announces Call to Discuss FDA IND Approval and Phase 2 Trial for Berubicin Dec 17, 2020 4:05pm EST
CNS Pharmaceuticals Announces FDA Approval of IND Application for its Brain Cancer Drug Candidate Berubicin Dec 17, 2020 9:00am EST
CNS Pharmaceuticals Featured in Syndicated Broadcast Covering Recent Announcements for Glioblastoma Multiforme (GBM) Therapy Nov 24, 2020 8:00am EST
CNS Pharmaceuticals and WPD Pharmaceuticals to Contribute Sponsorship to 2020 SNO Virtual Meeting Nov 19, 2020 8:00am EST
CNS Pharmaceuticals Announces FDA Filing of IND for its Brain Cancer Drug Berubicin Nov 17, 2020 8:00am EST
CNS Pharmaceuticals to Discuss Phase 2 Clinical Trial Design to be Submitted for FDA Review in Webcast at 4:30 PM ET Today Nov 12, 2020 8:00am EST
CNS Pharmaceuticals Announces Adaptive Trial Design For Berubicin Phase 2 Clinical Trial To Be Submitted for FDA Review Nov 09, 2020 8:00am EST
CNS Pharmaceuticals Completes Manufacturing of Berubicin for Phase 2 Clinical Trial Oct 29, 2020 8:00am EDT
